What is she best known for?
The fields of study she is best known for:
Her primary scientific interests are in Cancer research, Receptor tyrosine kinase, Tyrosine kinase, Molecular biology and Hepatocyte growth factor.
The Cancer research study combines topics in areas such as Cancer, Targeted therapy, Metastasis and Tumor progression.
The study incorporates disciplines such as Cell surface receptor, Proto-oncogene tyrosine-protein kinase Src and Platelet-derived growth factor receptor in addition to Receptor tyrosine kinase.
Silvia Giordano works mostly in the field of Tyrosine kinase, limiting it down to concerns involving Drug resistance and, occasionally, Lung cancer, KRAS, Cetuximab, Panitumumab and Growth factor receptor.
Her Hepatocyte growth factor research integrates issues from Cell culture, Epithelial polarity and Northern blot.
Her Cell biology study which covers Receptor that intersects with Downregulation and upregulation.
Her most cited work include:
- Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. (1064 citations)
- A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family (874 citations)
- Drug development of MET inhibitors : targeting oncogene addiction and expedience (709 citations)
What are the main themes of her work throughout her whole career to date?
Silvia Giordano mainly investigates Cancer research, Receptor tyrosine kinase, Tyrosine kinase, Cell biology and Cancer.
Her studies in Cancer research integrate themes in fields like Hepatocyte growth factor, Cancer cell, Carcinogenesis, Oncogene and Targeted therapy.
Her Receptor tyrosine kinase research is multidisciplinary, incorporating perspectives in Protein tyrosine phosphatase, Proto-oncogene tyrosine-protein kinase Src, ROR1, Platelet-derived growth factor receptor and Molecular biology.
In Tyrosine kinase, Silvia Giordano works on issues like Phosphorylation, which are connected to Tyrosine.
Her Cell biology study integrates concerns from other disciplines, such as Semaphorin, Receptor and C-Met.
Her work deals with themes such as Pathology, Oncology and Pharmacology, which intersect with Cancer.
She most often published in these fields:
- Cancer research (47.09%)
- Receptor tyrosine kinase (29.10%)
- Tyrosine kinase (28.04%)
What were the highlights of her more recent work (between 2016-2021)?
- Cancer research (47.09%)
- Cancer (22.22%)
- Internal medicine (15.34%)
In recent papers she was focusing on the following fields of study:
Her primary areas of investigation include Cancer research, Cancer, Internal medicine, Oncology and Cancer cell.
Her Cancer research study combines topics from a wide range of disciplines, such as Tyrosine kinase, Targeted therapy, Downregulation and upregulation and Transplantation.
Her research investigates the connection with Tyrosine kinase and areas like Epidermal growth factor receptor which intersect with concerns in AXL receptor tyrosine kinase, Hippo signaling pathway, Cell biology and Epithelial–mesenchymal transition.
Her biological study spans a wide range of topics, including EGFR inhibitors and Signal transduction, Receptor tyrosine kinase.
Her Cancer study incorporates themes from Cell culture and Clinical trial, Pathology.
Her Cancer cell research also works with subjects such as
- Oncogene together with Cell signaling, Autocrine signalling, Galectin-1 and Kinase activity,
- Kinase together with Lung cancer, Tumor microenvironment and Hepatocyte growth factor.
Between 2016 and 2021, her most popular works were:
- Increased Lactate Secretion by Cancer Cells Sustains Non-cell-autonomous Adaptive Resistance to MET and EGFR Targeted Therapies. (71 citations)
- Targeted therapies for gastric cancer: failures and hopes from clinical trials (55 citations)
- Biomarkers of primary resistance to trastuzumab in HER2-positive metastatic gastric cancer patients: the AMNESIA case-control study (39 citations)
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
